NCT05436314

Brief Summary

There are limited studies on the use of Manual Lymphatic Drainage (MLD) in fibromyalgia syndrome. Considering the possible mechanisms of action of MLD and the pathophysiology of fibromyalgia, more studies are needed to fully determine the effect of MLD on this syndrome. The aim of this study was to investigate the effectiveness of manual lymphatic drainage on symptom severity, pain intensity, pressure pain threshold and anxiety about pain in fibromyalgia syndrome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 23, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 29, 2022

Completed
26 days until next milestone

Study Start

First participant enrolled

July 25, 2022

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 25, 2023

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2024

Completed
Last Updated

March 6, 2025

Status Verified

March 1, 2025

Enrollment Period

1.1 years

First QC Date

June 23, 2022

Last Update Submit

March 4, 2025

Conditions

Keywords

fibromyalgiapainmanual lymphatic drainage

Outcome Measures

Primary Outcomes (3)

  • Fibromyalgia Impact Questionnaire (FIQ)

    The FIQ is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes.

    5 minutes

  • Pressure pain thresholds (PPT)

    Pressure pain thresholds in following three points, 7th cervical vertebra,6th thoracal vertebra and 3th lumbal vertebra were measured using a analog pressure algometer (Baseline, USA).

    10 minutes

  • Visual Analogue Scale

    A 0-100mm Visual Analogue Scale (VAS) will be used to assess pain intensity. The VAS is a scale on a straight line with a value of "0" indicating "no pain intensity" and a value of "100" indicating "severe pain". Participants will be asked to mark the pain they feel on this line.

    1 minutes

Secondary Outcomes (1)

  • Concerns About Pain

    5 minutes

Study Arms (2)

Manual Lymphatic Drainage Group

EXPERIMENTAL

Manual Lymphatic Drainage (MLD) in addition to medical treatment is applied to participants in this group.

Other: Manual Lymphatic DrainageDrug: Medical treatment

Sham Group

SHAM COMPARATOR

Sham Manual Lymphatic Drainage (MLD) in addition to medical treatment is applied to participants in this group.

Drug: Medical treatmentOther: Sham Manual Lymphatic Drainage

Interventions

Manual Lymphatic Drainage (MLD) is applied towards the flow direction of lymph vessels with special hand movements. MLD is made with very light, completely painless and rhythmic translational movements of the skin. MLD, by expert and trained physiotherapists (G.K, H.K) in this field. It will be applied with the techniques defined by Dr. Vodder. MLD ( to the neck region, abdominal region, axillary and inguinal lymph nodes) will be applied by following the lymphatic pathways specific to the anterior and posterior trunk, respectively. The treatment session will take approximately 45 minutes. It will be applied 5 days a week during 3 weeks.

Manual Lymphatic Drainage Group

The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.

Manual Lymphatic Drainage GroupSham Group

Sham MLD will be administered by MLD-trained physiotherapists (G.K, H.K) with a protocol that is far from techniques that reveal the physiological effects of MLD. Sham application consists of applications that do not follow the lymphatic pathways from distal to proximal to the trunk, neck, and abdominal region, and superficial breathing. The session will take approximately 45 minutes.

Sham Group

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • have fibromyalgia as defined by the criteria of the 2016 ACR
  • have Turkish as their native language
  • between 18 and 65 years of age

You may not qualify if:

  • Having cognitive impairment
  • Receiving routine physiotherapy and/or manual therapy, alternative/complementary therapies
  • Illiterate people
  • Diagnosed with endocrine, neuromuscular, infectious and inflammatory diseases
  • Diagnosed severe mental and psychological disorders
  • Having malignancy
  • Pregnant or people who breastfeed

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kutahya Health Sciences University Evliya Celebi Hospital

Kütahya, 43100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

FibromyalgiaPain

Interventions

Manual Lymphatic Drainage

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

MassageTherapy, Soft TissueMusculoskeletal ManipulationsComplementary TherapiesTherapeuticsDrainagePhysical Therapy ModalitiesRehabilitation

Study Officials

  • Gamze KURT, Ph.D.

    Kutahya Health Sciences University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ph.D.

Study Record Dates

First Submitted

June 23, 2022

First Posted

June 29, 2022

Study Start

July 25, 2022

Primary Completion

August 25, 2023

Study Completion

January 15, 2024

Last Updated

March 6, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations